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We aimed to assess the association between skin thickness and glycaemic control in children with type 1 diabetes.
Forty-five children (51% males) aged 10.5 ± 2.1 years were studied. Thickness of skin layers were determined by
ultrasonography, with participants having ultrasound scans of three anatomical regions (abdomen, thigh, and buttocks).
Poorer glycaemic control (increasing HbA1c values) was associated with greater thickness of the dermis (p = 0.015), with
an estimated thickening of 87 μm with every 1% increase in HbA1c. Our data suggest that dermal changes associated
with poorer glycaemic control in adults are also observed in childhood.
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Introduction
Children and adults with type 1 diabetes mellitus have
been shown to have thicker epidermis-dermis layer than
controls [1,2], but these observations are not always con-
sistent [3]. Previous studies suggested that neither the
presence of abnormal plantar fascia thickness in diabetic
adolescents [4] nor sclerodactyly in diabetic adults [5] was
associated with glycosylated haemoglobin (HbA1c) levels.
However, higher HbA1c levels (i.e. poorer glycaemic con-
trol) were associated with increased dermal thickness in
adults [2]. We aimed to assess whether a similar relation-
ship between skin thickness and glycaemic control occurs
in children with type 1 diabetes.Methods
Otherwise healthy children and adolescents aged 5–
14 years with type 1 diabetes mellitus were recruited
from the diabetes clinics at Starship Children’s Hospital,
Auckland, New Zealand [6]. Exclusion criteria included
moderate to severe lipohypertrophy, other medical con-
ditions such as coeliac disease or autoimmune thyroid* Correspondence: p.hofman@auckland.ac.nz
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unless otherwise stated.disease, associated syndromes (e.g. Down’s syndrome)
and other causes of diabetes (e.g. cystic fibrosis) [6].
Children with mild lipohypertrophy who were studied
had no measurements made in areas where adipose
thickening was noted.
Dermis and subcutis thicknesses were assessed using
ultrasound at five common injection sites: anterior abdo-
men 3–4 cm lateral to the umbilicus (left- and right-hand
sides), lateral mid-thigh (left and right thighs), and left
buttock. From a clinical perspective it is most useful to
understand skin thickness where insulin injections are ad-
ministered, as skin thickness may ultimately influence the
choice of needle length.
Dermal thickness was defined as the distance between
the air-skin surface interface and the proximal aspect of
the subcutaneous tissue layer, and included the small con-
tribution of the epidermis. Subcutis thickness was mea-
sured from the proximal subcutaneous fat boundary to
the underlying muscle fascia. Ultrasound was performed
using an ATL HDI 5000 ultrasound machine (Phillips
Healthcare, Best, Netherlands) and a 12 MHz linear array
transducer. The exact site of needle insertion was marked
prior to injection, and the transducer centered over this
point. A single measurement was obtained mid-transducer,
with cursors centered at the air-skin interface, the skin-
subcutaneous fat interface, and the fat-muscle fascia inter-
face. All ultrasound measurements were carried out by theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 The association between HbA1c levels and skin
thickness in diabetic children (n = 45), as predicted by
multivariate models. For the sake of clarity, only the mean value of
five samples for each individual (adjusted for confounding factors in
multivariate models) was plotted.
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optimize image quality by increasing the distance between
the transducer and the skin. This method of assessing
depth of skin layers has been well-validated previously [7].
Apart from simple correlations, random effect mixed
models with repeated measures (SAS v.9.3, SAS Institute
Inc. Cary, NC, USA) were used to assess the association
of HbA1c with skin thickness. Models included age, ana-
tomical region, side (left or right), sex, and body mass
index standard deviation score (BMISDS) as confound-
ing factors. Descriptive data are presented as means ±
standard deviations.
Ethics approval was provided by the Auckland District
Health Board Research Review Committee. Written in-
formed consent was obtained from parents/guardians, and
verbal or written consent from each child as appropriate
to their age.
Results
Forty-five children (51% males) with type 1 diabetes were
studied. Participants were aged 10.5 ± 2.1 years (range:
6.4–14.3 years) and of BMISDS 0.53 ± 1.01 (range: −1.61–
2.99). Mean HbA1c was 8.0 ± 1.1% (64 ± 12 mmol/mol),
with a range of 5.8–11.4% (40–101 mmol/mol). Higher
HbA1c values (poorer glycaemic control) were correlated
with increasing dermis thickness in buttocks (r = 0.35; p =
0.017), abdomen (r = 0.42; p = 0.004), and thigh (r = 0.44;
p = 0.002). HbA1c values were also positively correlated
with subcutis thickness in the abdomen (r = 0.37; p =
0.012), but not in buttocks (p = 0.10) or thigh (p = 0.45).
Multivariate analyses showed that poorer glycaemic con-
trol (increasing HbA1c values) was associated with greater
thickness of the dermis (p = 0.015), with an estimated thick-
ening of 87 μm with every 1% increase in HbA1c (Figure 1).
This association was observed despite adjustment for a
number of confounders, including BMISDS that was highly
associated with dermal thickness (p < 0.0001). There was
no association between glycaemic control and subcutis
thickness (p = 0.80).
Conclusions
Our study suggests that changes in the dermis associated
with poorer glycaemic control in adults [2] are also ob-
served in childhood. Our findings are in contrast to those
of Lo Presti et al., who observed no association between
HbA1c values and skin thickness or skin plus subcutis
thickness [8]. The observed effect in our cohort might
have resulted from the higher mean HbA1c (7.99 ± 1.09 vs
7.48 ± 0.77%; p = 0.011) and a wider range of HbA1c
values in our patients compared to that previous study.
The relatively small number of participants in our study
(n = 45) is a limitation. However, we obtained five mea-
surements per child over three anatomical regions to ac-
count for between-site variations, and all measurementwere performed by the same radiologist; thus, our data are
likely to be robust.
An asymptomatic but measureable thickening of the
skin commonly occurs in association with diabetes
mellitus [9]. The clinical relevance of the dermal thick-
ening observed in our study is unclear, but this thicken-
ing is one of a number of alterations in connective
tissue that are observed in diabetic patients [2]. Al-
though the mild skin thickening observed in our pa-
tients may not be clinically relevant, Buckingham et al.
suggested that changes akin to scleroderma (i.e. greater
thickening) may reflect generalized alterations in connect-
ive tissue in patients with diabetes, and possibly indicate
increased risk of microvascular complications [10].Competing interests
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